The Yale-University College London Clinical Research Partnership is a unique collaboration that combines the expertise of leading European scientists and clinicians to advance cardiovascular research with early device evaluation in the European arena. The current focus of this initiative is the Yale-UCL Device Development Program, and also includes several First-In-Man and CE-mark clinical trials for coronary and structural cardiovascular devices.
In addition to the Yale-UCL collaboration, Yale maintains close relationships with many other national and international research and education partners. These include strong ongoing connections in China with the China Cardiovascular Research Foundation, FuWai Hospital in Beijing, and China Interventional Therapeutics; as well as with leading international educational programs including TCT Asia Pacific, Transcatheter Cardiovascular Therapeutics, and EuroPCR.
United Kingdom: Yale-University College London
University College London
UCL Partners comprises five of London's biggest and best known hospitals and research centers:
- University College London
- Great Ormond Street Hospital for Children NHS Trust (GOSH)
- Moorfields Eye Hospital NHS Foundation Trust
- Royal Free Hampstead NHS Trust
- UCL Hospitals NHS Foundation Trust (UCLH)
UCL Interventional Cardiology facilities include 4 state-of-the-art catheterization laboratories and 4 operating rooms, employing 6 interventional cardiologists and 9 cardiothoracic surgeons. UCL physicians perform 2,100 cardiovascular interventional procedures annually, including a wide range of complex coronary and structural heart interventions and an active transcatheter valve program employing numerous investigational therapies.
In addition to extensive clinical facilities and a large cardiovascular case volume, UCL has the largest concentration of biomedical research in Europe and scored first in clinical medicine in UK's Government Research Assessment. It was designated as one of the UK's first academic health science centers by the Department of Health in March 2009.
Device Development Program
The objective of the Yale-UCL Device Development Program is to establish an integrated early device evaluation program to innovate and evaluate endovascular devices and biologics from concept to market.
The program's therapeutic focus is structural, congenital heart, coronary, peripheral, and endovascular device and biologics evaluations. This will be accomplished through Phase I though IV and post market trials.
In the preclinical phase, the Yale-UCL partnership draws on the Center for Computational Device Modeling and our GCP Animal Laboratory to innovate and evaluate devices using advanced imaging approaches and preclinical models including atherosclerotic swine. The clinical stage leverages the YCRG clinical research infrastructure and the combined clinical practices of the Yale-New Haven Hospital system and UCL Partners.
Current initiatives include international clinical trials of several cardiovascular devices, including First-in-Man and European CE Mark trials, with strategies in place to transition to US IDE trials.
Clinical trials that have been initiated as part of the Yale-UCL Collaboration include investigations of:
- Bioabsorbable stents and other novel pharmacological delivery systems
- Aortic arch embolic protection systems for use during TAVR
- Stentless, retrievable and repositionable second-generation percutaneous aortic valves
- Cerebral embolization during TAVR using diffusion-weighted MRI
- Valve devices for functional mitral regurgitation
- Transcatheter left ventricular reduction devices for LV dysfunction following MI